Our research group uses an integrated structural biology and biophysical approach combined with functional studies to understand the inhibition mechanisms of novel protein targets in human diseases and translate it to develop novel therapeutics.

We are interested in elucidating the molecular basis of the inhibition mechanism of novel drug targets. In collaboration with other groups in academia and industry, we are improving the potency and selectivity of inhibitors with biomedical applications.

Selected Publications

– Swale, C., Bougdour, A., Gnahoui-David, A., Tottey, J., Georgeault, S., Laurent*,  F.,  Palencia*†,   A.    et al. Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls Cryptosporidium infection. Science Trans. Medicine Nov 6;11(517). doi: 10.1126 (2019). *Corresponding and †Lead Author.

– *Palencia, A., Bougdour, A., et al. Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis. EMBO Molecular Medicine 9: 385-394 (2017)Highlighted in:  France 3 news.

– *Palencia, A., Li, X., et al. Discovery of Novel Protein Synthesis Inhibitors of M.tuberculosis That Target Leucyl-tRNA Synthetase. Antimicrob Agent Chemother 60(10):5817-27 (2016)

– Chopra, S.*, Palencia, A.*,  et al. Structural characterisation of antibiotic self-immunity tRNA synthetase in plant tumour biocontrol agent. Nature comm 7:12928 (2016).  

Palencia, A.*,Chopra, S.*, et al. Plant tumour biocontrol agent employs a tRNA-dependent mechanism to inhibit leucyl-tRNA synthetase. Nature comm 4, 1417 (2013).

– Palencia, A., Crepin, T., et al. Structural dynamics of the aminoacylation and proofreading functional cycle of bacterial leucyl-tRNA synthetase. Nature Struct. & Mol. Biol.  19, 677-84 (2012).

Full publication list

Palencia’s Group, Institute for Advanced Biosciences (IAB), Inserm U1209, CNRS UMR5309/ Univ. Grenoble-Alpes, Grenoble, Grenoble

Contact: andres.palencia [ at] univ-grenoble-alpes.fr